AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca, in collaboration with Ionis Pharmaceuticals, is conducting a Phase 3 study titled ‘CARDIO-TTRansform’ to evaluate the efficacy and safety of eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR CM). The study aims to assess how well eplontersen, administered via subcutaneous injections, performs compared to a placebo in improving patient outcomes while receiving standard care.
The intervention being tested is eplontersen, a drug administered through subcutaneous injections every four weeks. Its purpose is to treat ATTR CM, a condition characterized by the buildup of amyloid proteins in the heart tissue.
This study is designed as a double-blind, randomized, placebo-controlled trial involving 1,438 participants. It follows a parallel intervention model with both participants and investigators masked to the treatment allocations. The primary goal is to determine the treatment’s effectiveness.
The study began on March 13, 2020, and is currently active but not recruiting new participants. The last update was submitted on August 6, 2025, indicating ongoing progress and data collection.
The outcome of this study could significantly influence AstraZeneca’s market position, potentially boosting investor confidence if results are positive. The development of effective treatments for ATTR CM could also impact the competitive landscape, as companies race to address this unmet medical need.
The study is ongoing, with further details available on the ClinicalTrials portal.